Important notice regarding Inveltys

Posted in Latest News on August 7, 2019.

Important notice regarding Inveltys:

The board approved Inveltys (loteprednol etabonate ophthalmic suspension) 1% for addition to Rule 64B13-18.002. Effective August 5, 2019, Licensees are now permitted to prescribe Inveltys.



More Latest News

Electronic Prescribing Requirements
October 21, 2019

Click here for the new requirements requiring prescribers to generate and transmit all prescriptions electronically Continue reading


Important Notice regarding Dextenza and Klarity-C
October 15, 2019

The Board of Optometry has approved Dextenza (dexamethasone ophthalmic insert) 0.4 mg and Klarity-C (cyclosporine) 0.1% for addition to Rule 64B13-18.002. Continue reading